Shijiazhuang Yiling Pharmaceutical (002603.CH) - Doubts About COVID-19 Drug and the Concerns Behind

333 Views19 Apr 2022 10:57
There are doubts about the efficiency of Lianhua Qingwen for COVID-19. The clinical trails are not persuasive. Yiling's performance is not sustainable after COVID. So, investors should remain cautious
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x